Gray Wealth Management Inc. Has $251,000 Position in Pfizer Inc. (NYSE:PFE)

Gray Wealth Management Inc. cut its position in Pfizer Inc. (NYSE:PFE) by 13.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 9,461 shares of the biopharmaceutical company’s stock after selling 1,531 shares during the period. Gray Wealth Management Inc.’s holdings in Pfizer were worth $251,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Creative Financial Designs Inc. ADV raised its stake in Pfizer by 4.7% during the 4th quarter. Creative Financial Designs Inc. ADV now owns 44,882 shares of the biopharmaceutical company’s stock worth $1,191,000 after buying an additional 2,023 shares during the period. IMG Wealth Management Inc. acquired a new position in Pfizer in the fourth quarter valued at about $76,000. SlateStone Wealth LLC raised its position in shares of Pfizer by 5.7% during the fourth quarter. SlateStone Wealth LLC now owns 9,497 shares of the biopharmaceutical company’s stock worth $252,000 after purchasing an additional 508 shares during the period. GWN Securities Inc. bought a new position in shares of Pfizer during the 4th quarter valued at about $1,633,000. Finally, Envestnet Portfolio Solutions Inc. grew its position in shares of Pfizer by 3.6% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 600,366 shares of the biopharmaceutical company’s stock valued at $15,928,000 after purchasing an additional 20,991 shares during the period. 68.36% of the stock is owned by institutional investors.

Analyst Ratings Changes

PFE has been the topic of several research analyst reports. Bank of America restated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. UBS Group cut their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research note on Wednesday, March 12th. Citigroup dropped their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Finally, StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Stock Up 0.5 %

Pfizer stock opened at $25.74 on Monday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company’s 50-day moving average is $26.24 and its 200-day moving average is $27.12. The firm has a market capitalization of $145.85 billion, a PE ratio of 18.25, a P/E/G ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the prior year, the company earned $0.10 earnings per share. The business’s revenue for the quarter was up 24.7% compared to the same quarter last year. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.